Evaluating the Safety and Efficacy of Carbocisteine in the Treatment of Nonalcoholic Fatty Liver Disease Patients

Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-65
SponsorTanta University

About this trial

Nonalcoholic fatty liver disease (NAFLD) is a global public health concern, and the leading cause of chronic liver disease, especially in developed countries. NAFLD is characterized by lipid accumulation in the liver not attributed to other causes. Lifestyle interventions, including dietary modification and exercise, remain the cornerstone of NAFLD treatment. Pharmacological treatments aimed primarily at improving liver disease should generally be limited to those with biopsy-proven NASH and fibrosis.

Eligibility criteria

Qualifiers

Either male or female adult patients (>18 years) with fatty liver diagnosis by using upper abdominal ultrasound echography

Disqualifiers

Pregnant and/or lactating women

Excessive alcohol use (defined as an average alcohol intake > 30 g per day in men and > 20 g per day in women)

Other etiology of chronic liver diseases such as viral hepatitis, drug-induced hepatitis, autoimmune hepatitis.

patients suffering from chronic kidney disease, and hyper/hypoparathyroidism

Trial design

Treatments tested in this trial

  • Carbocysteine 375 MG
  • Physical activity, walking, and calorie restriction

Treatment groups

46 Participants
are divided into 2 treatment groups

Locations

1
Tanta Unuversity31527, Tanta Egypt

Sponsors and collaborators

Tanta University

Lead sponsor